Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis offloads ophthalmology assets for $2.5bn
The deal value comprised an upfront cash payment of $1.75bn, apart from further milestone payments in the future. The parties entered an agreement in this regard in June 2023.
The deal value comprised an upfront cash payment of $1.75bn, apart from further milestone payments in the future. The parties entered an agreement in this regard in June 2023.
An investigational activin signalling inhibitor, sotatercept is intended for usage in adult PAH patients. A regulatory decision on the approval of the therapy is anticipated on 26 March
The designation has been awarded for IDE161 to treat adult patients with advanced or metastatic hormone receptor-positive (HR+), Her2- breast cancer with germline or somatic BRCA 1/2 mutations.
The regulator also approved LIKMEZ as the brand name for ATI-1501. Saptalis is a manufacturing and commercialisation partner of Appili Therapeutics, which has developed ATI-1501 as a liquid
ALTUVIIIO, also known as efanesoctocog alfa, is an antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein used for perioperative management of bleeding, controlling bleeding episodes, and routine prophylaxis. The recommended
This acquisition aligns with Lupin’s strategic goal to strengthen its position in the key therapeutic portfolio in India. The brands agreed to be acquired consists of Piclin (Picosulphate
The company submitted the application in August this year seeking approval for the initiation of Phase I clinical trial of KB408. The regulator, after the 30-day review of
With an area of around 7,000m2, the new location features the XBCM2 dual-function facility for bioconjugate drug substance and antibody intermediates production. It also comprises the XDP2 facility,
Cabotegravir is indicated for use in high-risk adults and adolescents aged a minimum of 12 years weighing at least 35 kg. It is claimed to be the first
KT-333 is a highly selective degrader of STAT3, a transcriptional regulator that is linked to inflammatory and autoimmune diseases as well as various cancers. The company is also